Literature DB >> 17341992

New antihypertensive agents: will they work in blacks?

Keith C Ferdinand.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17341992      PMCID： PMC8110148          DOI： 10.1111/j.1524-6175.2007.06464.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  16 in total

1.  Nebivolol: a third-generation beta-blocker that augments vascular nitric oxide release: endothelial beta(2)-adrenergic receptor-mediated nitric oxide production.

Authors:  M A Broeders; P A Doevendans; B C Bekkers; R Bronsaer; E van Gorsel; J W Heemskerk; M G Egbrink; E van Breda; R S Reneman; R van Der Zee
Journal:  Circulation       Date:  2000-08-08       Impact factor: 29.690

2.  NICE removes beta blockers as first line treatment for hypertension.

Authors:  Susan Mayor
Journal:  BMJ       Date:  2006-07-01

3.  Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.

Authors:  Jackson T Wright; J Kay Dunn; Jeffrey A Cutler; Barry R Davis; William C Cushman; Charles E Ford; L Julian Haywood; Frans H H Leenen; Karen L Margolis; Vasilios Papademetriou; Jeffrey L Probstfield; Paul K Whelton; Gabriel B Habib
Journal:  JAMA       Date:  2005-04-06       Impact factor: 56.272

4.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

5.  Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction.

Authors:  D V Exner; D L Dries; M J Domanski; J N Cohn
Journal:  N Engl J Med       Date:  2001-05-03       Impact factor: 91.245

6.  Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren.

Authors:  Alice Stanton; Chris Jensen; Juerg Nussberger; Eoin O'Brien
Journal:  Hypertension       Date:  2003-11-03       Impact factor: 10.190

7.  Department of veterans Affairs single-drug therapy of hypertension study. Revised figures and new data. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.

Authors:  B J Materson; D J Reda; W C Cushman
Journal:  Am J Hypertens       Date:  1995-02       Impact factor: 2.689

8.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

9.  Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study.

Authors:  Stevo Julius; Michael H Alderman; Gareth Beevers; Björn Dahlöf; Richard B Devereux; Janice G Douglas; Jonathan M Edelman; Katherine E Harris; Sverre E Kjeldsen; Shawna Nesbitt; Otelio S Randall; Jackson T Wright
Journal:  J Am Coll Cardiol       Date:  2004-03-17       Impact factor: 24.094

10.  Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism.

Authors:  J R Cockcroft; P J Chowienczyk; S E Brett; C P Chen; A G Dupont; L Van Nueten; S J Wooding; J M Ritter
Journal:  J Pharmacol Exp Ther       Date:  1995-09       Impact factor: 4.030
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.